Information for Healthcare Providers
Lorlatinib
Brand name: Lorbrena
Lorlatinib is a third-generation ALK inhibitor with intracranial activity and control of CNS disease in patients with ALK-positive NSCLC, including those with baseline brain metastases.
Alectinib
Brand name: Alecensa
Alectinib is a second-generation ALK inhibitor that provides effective systemic and CNS disease control in ALK-positive NSCLC and is commonly used as first-line therapy.
Crizotinib
Brand name: Xalkori
Crizotinib is a first-generation ALK inhibitor that demonstrated clinical benefit in ALK-positive NSCLC but has limited CNS penetration compared with newer ALK inhibitors.